These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 39158365)

  • 1. Valuing quality of life for economic evaluations in cancer: navigating multiple methods.
    Ng CA; De Abreu Lourenco R; Viney R; Norman R; King MT; Kim N; Mulhern B
    Expert Rev Pharmacoecon Outcomes Res; 2024 Aug; ():1-14. PubMed ID: 39158365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients-Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs.
    Pilz MJ; Seyringer S; Al-Naesan I; King MT; Bottomley A; Norman R; Schlosser L; Hell T; Gamper EM;
    Pharmacoecon Open; 2024 Jul; 8(4):627-640. PubMed ID: 38696019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The EORTC QLU-C10D is a valid cancer-specific preference-based measure for cost-utility and health technology assessment in the Netherlands.
    Pilz MJ; Seyringer S; Hallsson LR; Bottomley A; Jansen F; King MT; Norman R; Rutten MJ; Verdonck-de Leeuw IM; Siersema PD; Gamper EM
    Eur J Health Econ; 2024 Dec; 25(9):1539-1555. PubMed ID: 38483665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The EORTC QLU-C10D: The Canadian Valuation Study and Algorithm to Derive Cancer-Specific Utilities From the EORTC QLQ-C30.
    McTaggart-Cowan H; King MT; Norman R; Costa DSJ; Pickard AS; Regier DA; Viney R; Peacock SJ
    MDM Policy Pract; 2019; 4(1):2381468319842532. PubMed ID: 31245606
    [No Abstract]   [Full Text] [Related]  

  • 5. The European Organisation for Research and Treatment of Cancer Quality of Life Utility-Core 10 Dimensions: Development and Investigation of General Population Utility Norms for Canada, France, Germany, Italy, Poland, and the United Kingdom.
    Pilz MJ; Nolte S; Liegl G; King M; Norman R; McTaggart-Cowan H; Bottomley A; Rose M; Kemmler G; Holzner B; Gamper EM;
    Value Health; 2023 May; 26(5):760-767. PubMed ID: 36572102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30.
    King MT; Viney R; Simon Pickard A; Rowen D; Aaronson NK; Brazier JE; Cella D; Costa DSJ; Fayers PM; Kemmler G; McTaggart-Cowen H; Mercieca-Bebber R; Peacock S; Street DJ; Young TA; Norman R;
    Pharmacoeconomics; 2018 Feb; 36(2):225-238. PubMed ID: 29270835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. United States Utility Algorithm for the EORTC QLU-C10D, a Multiattribute Utility Instrument Based on a Cancer-Specific Quality-of-Life Instrument.
    Revicki DA; King MT; Viney R; Pickard AS; Mercieca-Bebber R; Shaw JW; Müller F; Norman R
    Med Decis Making; 2021 May; 41(4):485-501. PubMed ID: 33813946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. French Value-Set of the QLU-C10D, a Cancer-Specific Utility Measure Derived from the QLQ-C30.
    Nerich V; Gamper EM; Norman R; King M; Holzner B; Viney R; Kemmler G
    Appl Health Econ Health Policy; 2021 Mar; 19(2):191-202. PubMed ID: 32537694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing health-related quality of life in cancer survivors: factors impacting on EORTC QLU-C10D-derived utility values.
    van Gelder T; Mulhern B; Schoormans D; Husson O; De Abreu Lourenço R
    Qual Life Res; 2020 Jun; 29(6):1483-1494. PubMed ID: 31938965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimation of Health-Related Utilities for
    Soare IA; Leeuwenkamp O; Longworth L
    Pharmacoecon Open; 2021 Dec; 5(4):715-725. PubMed ID: 34260017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D.
    Jansen F; Verdonck-de Leeuw IM; Gamper E; Norman R; Holzner B; King M; Kemmler G;
    Qual Life Res; 2021 Jul; 30(7):2009-2019. PubMed ID: 33512653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chinese utility weights for the EORTC cancer-specific utility instrument QLU-C10D.
    Cao Y; Xu J; Norman R; King MT; Kemmler G; Huang W; Luo N
    Qual Life Res; 2024 Sep; ():. PubMed ID: 39269580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The EORTC QLU-C10D discrete choice experiment for cancer patients: a first step towards patient utility weights.
    Gamper EM; King MT; Norman R; Loth FLC; Holzner B; Kemmler G;
    J Patient Rep Outcomes; 2022 May; 6(1):42. PubMed ID: 35507194
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EORTC QLU-C10D value sets for Austria, Italy, and Poland.
    Gamper EM; King MT; Norman R; Efficace F; Cottone F; Holzner B; Kemmler G;
    Qual Life Res; 2020 Sep; 29(9):2485-2495. PubMed ID: 32458409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. German value sets for the EORTC QLU-C10D, a cancer-specific utility instrument based on the EORTC QLQ-C30.
    Kemmler G; Gamper E; Nerich V; Norman R; Viney R; Holzner B; King M;
    Qual Life Res; 2019 Dec; 28(12):3197-3211. PubMed ID: 31485913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preference-based measures to obtain health state utility values for use in economic evaluations with child-based populations: a review and UK-based focus group assessment of patient and parent choices.
    Wolstenholme JL; Bargo D; Wang K; Harnden A; Räisänen U; Abel L
    Qual Life Res; 2018 Jul; 27(7):1769-1780. PubMed ID: 29564713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valuation of the EORTC Quality of Life Utility Core 10 Dimensions (QLU-C10D) in a Multi-ethnic Asian Setting: How Does Having Cancer Matter?
    Gandhi M; Kanesvaran R; Rashid MFBH; Chong DQ; Chay WY; Tan RL; Norman R; King MT; Luo N
    Pharmacoeconomics; 2024 Dec; 42(12):1413-1425. PubMed ID: 39325297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The EORTC QLU-C10D: the Hong Kong valuation study.
    Xu RH; Wong EL; Luo N; Norman R; Lehmann J; Holzner B; King MT; Kemmler G;
    Eur J Health Econ; 2024 Jul; 25(5):889-901. PubMed ID: 37768519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges in health state valuation in paediatric economic evaluation: are QALYs contraindicated?
    Ungar WJ
    Pharmacoeconomics; 2011 Aug; 29(8):641-52. PubMed ID: 21604821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the Content Validity of Preference-Based Measures in Cancer.
    Gibson AEJ; Longworth L; Bennett B; Pickard AS; Shaw JW
    Value Health; 2024 Jan; 27(1):70-78. PubMed ID: 37879402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.